The Aging Brain Initiative (ABI), galvanizes a powerful collaboration across MIT to pursue innovative research that produces new insights, potential therapies, and technologies. The ABI is distinguished both by its systems-wide approach to neurodegenerative disease and achieving practical results, such as our GENUS light and sound therapy that has shown encouraging improvements in early Alzheimer’s patients in Phase 2 trials. For more information and many more examples, see our 2024 ABI Newsletter.
Your support is needed now more than ever! Please join us in fighting age-related neurodegeneration with science!